Zosano Pharma Corp short interest in 2021
In 2021, Zosano Pharma Corp's disclosed short interest ran from 7.84% of shares outstanding on 15 Jan 2021 to 3.83% on 31 Dec 2021, a change of -4.01 percentage points. The year's high was 8.76% on 12 Feb 2021 and its low 3.47% on 15 Nov 2021, averaging 6.00% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.10 days on 30 Jul 2021. Full history: Zosano Pharma Corp.
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022
2021 in figures
- Start of year
- 7.84% (15 Jan 2021)
- End of year
- 3.83% (31 Dec 2021)
- Change
- -4.01 pp
- High
- 8.76% (12 Feb 2021)
- Low
- 3.47% (15 Nov 2021)
- Average
- 6.00%
- Highest days to cover
- 7.10 (30 Jul 2021)
- SEC filings marked
- 8
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 7.84% | 1.00 | |
| 29 Jan 2021 | 8.06% | 1.00 | |
| 12 Feb 2021 | 8.76% | 1.00 | |
| 26 Feb 2021 | 8.24% | 1.65 | |
| 15 Mar 2021 | 7.73% | 2.32 | 10-K filed, results (8-K) |
| 31 Mar 2021 | 7.39% | 2.01 | |
| 15 Apr 2021 | 7.50% | 5.53 | |
| 30 Apr 2021 | 7.20% | 3.05 | |
| 14 May 2021 | 6.53% | 5.63 | 10-Q filed, results (8-K) |
| 28 May 2021 | 6.17% | 1.97 | |
| 15 Jun 2021 | 6.78% | 2.37 | |
| 30 Jun 2021 | 6.91% | 5.30 | |
| 15 Jul 2021 | 6.76% | 5.55 | |
| 30 Jul 2021 | 6.81% | 7.10 | |
| 13 Aug 2021 | 5.69% | 7.00 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 4.25% | 4.03 | |
| 15 Sep 2021 | 4.44% | 4.61 | |
| 30 Sep 2021 | 4.18% | 6.04 | |
| 15 Oct 2021 | 3.78% | 5.17 | |
| 29 Oct 2021 | 3.61% | 3.81 | |
| 15 Nov 2021 | 3.47% | 1.19 | 10-Q filed, results (8-K) |
| 30 Nov 2021 | 4.01% | 1.00 | |
| 15 Dec 2021 | 4.11% | 4.57 | |
| 31 Dec 2021 | 3.83% | 3.88 |
See also: Zosano Pharma Corp's full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.